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SurveillanceThe measurement of virus-specific neutralising antibodies represents the ‘‘gold-standard” for diagnostic
serology. For animal morbilliviruses, such as peste des petits ruminants (PPRV) or rinderpest virus (RPV),
live virus-based neutralisation tests require high-level biocontainment to prevent the accidental escape
of the infectious agents. In this study, we describe the adaptation of a replication-defective vesicular
stomatitis virus (VSVDG) based pseudotyping system for the measurement of neutralising antibodies
against animal morbilliviruses. By expressing the haemagglutinin (H) and fusion (F) proteins of PPRV
on VSVDG pseudotypes bearing a luciferase marker gene, neutralising antibody titres could be measured
rapidly and with high sensitivity. Serological responses against the four distinct lineages of PPRV could be
measured simultaneously and cross-neutralising responses against other morbilliviruses compared.
Using this approach, we observed that titres of neutralising antibodies induced by vaccination with live
attenuated PPRV were lower than those induced by wild type virus infection and the level of cross-
lineage neutralisation varied between vaccinates. By comparing neutralising responses from animals
infected with either PPRV or RPV, we found that responses were highest against the homologous virus,
indicating that retrospective analyses of serum samples could be used to confirm the nature of the orig-
inal pathogen to which an animal had been exposed. Accordingly, when screening sera from domestic
livestock and wild ruminants in Tanzania, we detected evidence of cross-species infection with PPRV,
canine distemper virus (CDV) and a RPV-related bovine morbillivirus, suggesting that exposure to animal
morbilliviruses may be more widespread than indicated previously using existing diagnostic techniques.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Once the scourge of European, African and Asian livestock and
wild ruminants, rinderpest virus (RPV) is only the second virus in
history after smallpox to be eradicated by vaccination. RPV is amorbillivirus, a close relative of measles virus (MeV) and peste
des petits ruminants (PPRV). Like rinderpest, PPR is now being con-
sidered for global eradication by vaccination [1]. PPR has spread
over the last decade and is now endemic in many areas of Africa,
the Middle East, Central and Southern Asia and into China. PPRV
causes a devastating disease in small ruminants, threatening both
food security and the livelihoods of smallholders [2,3]. As such, PPR
has been selected as a top priority disease to be addressed by the
World Organization for Animal Health (OIE), with a global plan
for eradication by 2030 [4].
Goats vaccinated with RPV-derived vaccines resist PPRV infec-
tion [5–7]. For example, following vaccination with a vaccinia
RPV recombinant, the vaccinates initially produced an RPV-
specific response prior to challenge, with no cross-reactive PPRV
antibodies [7]. However, following challenge with PPRV and
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increased significantly, consistent with the PPRV challenge boost-
ing the RPV-specific response [7]. Similarly, PPRV vaccines elicit
both PPRV and RPV neutralising antibodies [8] and measles vacci-
nes cross-prime an anti-canine distemper virus (CDV) response in
dogs [9]. While the induction of cross-neutralising antibodies is a
common feature of exposure to morbilliviruses, the strength and
specificity of the response varies between viral species.
The ‘‘gold standard” for measuring morbillivirus-specific anti-
bodies is the virus neutralisation test [10]. However, classical tests
for neutralising antibodies are restricted to viral strains that are
amenable to propagation in cell culture. During the adaptation of
the virus for growth in cell culture, the biological properties of
the virus may alter dramatically to suit the new ex vivo environ-
ment and the availability of potential viral receptors [11–19]. As
the receptor binding domains of the morbilliviral haemagglutinins
are targets for neutralising antibodies [20], alterations in receptor
binding that facilitate infection in vitromay alter the conformation
of the viral haemagglutinin, modulating sensitivity to neutralising
antibodies. If biologically-relevant neutralising antibody responses
are to be quantified accurately, assays that utilize primary field
strains of virus and their cognate receptors are required. By gener-
ating viral ‘‘pseudotypes” bearing both the haemagglutinin (H) and
fusion (F) proteins of the morbillivirus [11,21], neutralising anti-
body responses may be measured against primary, field isolates
of the morbillivirus. Moreover, as viral pseudotype-based neutral-
isation assays are not constrained by the ability of the primary
morbillivirus to grow in the target cell, inter-assay variability is
minimized. Finally, where the viruses being studied present a sig-
nificant biohazard, pseudotype-based assays circumvent the need
for high-level bio-containment.
In this study we examined the neutralisation of ruminant mor-
billiviruses by sera from animals exposed to either PPRV or RPV.
We demonstrate that while cross-neutralisation is evident
between the two morbilliviruses, the strength and breadth of the
response against the two viruses differs markedly. Further, we
identify an RPV-specific neutralising activity, indicative of the cir-
culation of an RPV-related bovine morbillivirus.2. Materials and methods
2.1. Cell lines and sera
HEK293 [22] and HEK293T cells were maintained in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10% foetal
bovine serum, 100 IU/ml penicillin, 100 lg/ml streptomycin,
2 mM glutamine and 0.11 mg/ml sodium pyruvate. Media for
293T cells and 293 cells stably expressing canine SLAM were sup-
plemented with 400 lg/ml G418. All media and supplements were
obtained from Life Technologies Ltd., Paisley, UK. Sera were col-
lected from ruminants exposed to PPRV, RPV or PPRV and RPV vac-
cines. Samples from cattle vaccinated with live attenuated PPRV,
RPV, and wild type PPRV have been described previously [23]. Mis-
cellaneous sera from goats, sheep and cattle infected with either
PPRV or RPV were obtained from The Pirbright Institute, Surrey,
UK and the Joint United Nations Food and Agriculture Organization
(FAO) and International Atomic Energy Agency (IAEA) Biotechnol-
ogy and Agriculture Laboratories (Joint FAO/IAEA), Seibersdorf,
Austria.2.2. Eukaryotic expression vectors and recombinant viruses
The recombinant vesicular stomatitis virus (VSV) in which the
glycoprotein (G) gene has been deleted (VSVDG) and replaced with
firefly luciferase (luc) has been described [24,25] and was kindlyprovided by Michael Whitt, Memphis, TN, USA. The construction
of the RPV H and F expression plasmids and those for the vaccine
strain of PPRV (PPRV/Nigeria/75/1) has been previously described
[23]. Primary PPRV H and F cDNAs were amplified from viral
RNA. PPRV containing supernatants from cultures of PPRV isolates
Senegal 1969 [26] (lineage I), Benin 2010 [27] (lineage II), Kenya
2011 [28] (lineage III) and Ethiopia 2010 (lineage IV, Joint FAO/
IAEA PPRV Bank, Seibersdorf, Austria) were mixed with RLT lysis
buffer (QIAgen) and RNA prepared as per manufacturer’s instruc-
tions using a QIAamp Viral RNA Mini kit (QIAgen). This RNA was
then used to prepare first strand cDNA (Transcriptor First Strand
cDNA Synthesis Kit, Roche) and used as a template in PCR reactions
using Q5 high fidelity DNA polymerase (see Supplementary Meth-
ods for details of primers). Amplification products were digested
with SalI and NotI and cloned into the vector VR1012 (Vical Inc.).
The nucleic acid sequences of all amplified cDNAs were deter-
mined externally (LIGHTrun Sequencing Service, GATC Biotech
AG, Cologne, Germany). All oligonucleotide primers were obtained
from Integrated DNA Technologies, Leuven, Belgium.
2.3. VSVDGluc pseudotype preparation
293T cells were transfected with the H and F expression vectors
from the respective morbillivirus, followed by super-infection with
VSVDGluc (VSVG) as described [24,25]. Supernatants were har-
vested and titred on 293dogSLAM cells [24,25]. Luciferase activity
was measured by the addition of Steadylite plusTM (Perkin Elmer)
and a Microbeta 1450 Jet luminometer (Perkin Elmer). The viral
titre [50% tissue culture infectious dose (TCID50)] was calculated
using the Spearman-Kärber formula [29].
2.4. Pseudotype-based neutralisation assay
2  104 293-dogSLAM cells were plated into each well of a 96-
well plate (Culturplate-96, Perkin Elmer, Coventry, UK). Fourfold
serum dilutions were prepared in triplicate in complete medium
ranging from 1:8 to 1:32768. The diluted serum samples were then
added to the 293-dogSLAM cells followed by 2.5  103 TCID50 of
each VSVDGluc pseudotype. Luciferase activity was measured at
48–72 h post-plating and antibody titres calculated by interpolat-
ing the point at which there was a 90% reduction in luciferase
activity (90% neutralisation, inhibitory concentration 90 or IC90)
[30].
2.5. Live virus-based PPRV neutralisation assay
Virus neutralising activity in sera from cattle vaccinated with
live attenuated RPV and PPRV vaccines was assessed in a 96-well
plate based micro-neutralisation assay as per the standard OIE
specified procedure [10]. The target virus was PPRV Nigeria/75/1
and the target cells were Vero dogSLAM. The neutralising titre
was expressed as the reciprocal of the antibody dilution at which
50% of the wells showed virus growth.
2.6. PPRV cELISA
Antibodies against PPRV H in African sera were detected by
ELISA using a competitive ELISA (The Pirbright Institute, Surrey
and BDSL, Irvine, UK) as per the manufacturers’ instructions.
Briefly, inactivated PPRV is coated onto an ELISA plate prior to
the addition of test and control sera in the presence of a mono-
clonal antibody against PPRV H. Antibodies within the test sample
compete for binding with the anti-H monoclonal antibody, binding
of which is then quantified using an anti-mouse IgG horseradish
peroxidase (HRP) conjugated antibody. The percent inhibition
(PI) of monoclonal antibody binding for each test sample is
5738 N. Logan et al. / Vaccine 34 (2016) 5736–5743calculated in comparison with positive and negative control sera.
The diagnostic threshold for the assay is set at 50% PI of the mon-
oclonal antibody control. A PI value of <25% is considered negative.3. Results
3.1. Neutralisation of PPRV pseudotypes by sera from vaccinated and
infected animals
Neutralising antibody titres were measured in sera from cattle
infected previously [23] with either PPRV/Ivory Coast/89 (IC89,
wild type lineage 1), PPRV/Nigeria/75/1 (N75, vaccine lineage 2),
PPRV/Sungri/96 (S96, vaccine lineage 4) or the Plowright vaccine
strain of RPV (RBOK). Sera were screened for ability to neutralize
pseudotypes bearing the glycoproteins of the widely used PPRV
vaccine strain N75, four field strains representative of lineages 1–
4 (Senegal 1969, Benin 2010, Kenya 2011 and Ethiopia 2010),
and RPV Kabete O. All pre-challenge sera were negative for morbil-
livirus neutralising antibodies (titres < 16). Sera from IC89 infected
animals displayed high antibody titres against each of the five
PPRV strains (Fig. 1A–E) and cross-neutralized RPV albeit less effi-
ciently than PPRV (Fig. 1F). Sera raised against IC89 neutralized
Senegal 1969 (Fig. 1A) and N75 (Fig. 1E) (lineages 1 and 2 respec-
tively) most efficiently. Strong activity was also noted against
Benin 2010 (Fig. 1B) (lineage 2). Weaker responses were detected
against Kenya 2011 (Fig. 1C) and Ethiopia 2010 (Fig. 1D) (lineages
3 and 4 respectively), the titres being significantly lower than those
against lineages 1 and 2 (Wilcoxon matched pairs signed rank test,
p < 0.05).
Infection with the vaccine strains N75 and S96 induced sub-
stantially lower antibody titres per se. Titres induced by N75 infec-
tion were highest against the lineage 2 N75 (homologous strain)
and Benin 2010 strains. Neutralisation of lineage 3 Kenya 2011
by sera from the N75 vaccinates (Fig. 1C) was significantly less effi-
cient compared to homologous virus. The relatively poor neutrali-
sation of Kenya 2011 extended to the animals infected with the
lineage 4 vaccine strain S96 (Fig. 1C), titres being significantly
lower than those against all other viruses (p < 0.05). While neither
the N75 or S96 vaccinates developed RPV cross-neutralising anti-
bodies, the RPV vaccinates developed PPRV cross-neutralising anti-
bodies at levels comparable to those induced by the N75 or S96
vaccines, consistent with the cross-protection against PPRV
induced by RPV vaccines [5–7].Virus i
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Fig. 1. Neutralising antibody titres in cattle following PPRV or RPV inoculation. Four grou
(N75), PPRV/Sungri/96 (S96) or RPV/RBOK (RPV). Sera were tested at 4 weeks post-infect
1969, (B) Benin 2010, (C) Kenya 2011, (D) Ethiopia 2010 or (E) Nigeria 75/1 strains of PPR
in triplicate and screened for neutralising activity against each VSV(PPRV) pseudotype. A
no serum control. Mean ± SEM (n = 6) is shown for each group.3.2. Detection of neutralising antibodies in sera from ruminants in
Africa
The accurate identification of PPRV-exposed animals in the field
is critical to eradication campaigns and serological tests can facili-
tate the identification of animal reservoirs of infection in cases
where viral genomic material is undetectable in blood or body flu-
ids. We screened a panel of Tanzanian ruminant sera (goats (C.
aegagrus hircus), cattle (B. taurus), buffalo (S. caffer) and gazelle
(G. Thomsonii and G. Grant)) from areas reported previously to har-
bour PPRV. The buffalo and gazelle sera had been screened previ-
ously by cELISA and classed as ‘‘negative” (<50% inhibition on
cELISA), the sera which tested positive by ELISA having been sent
to The Pirbright Institute for further study. Buffalo sera were col-
lected across the Serengeti National Park (SNP) from 2005 to
2012. The goat sera, collected during 2012, came from the NCA, a
region that had undergone a PPRV vaccination campaign in
2011–2012.
The 27 gazelle sera tested negative for neutralising antibodies
against PPRV, in agreement with the cELISA test findings
(Fig. 2A). In contrast, 16 of the 42 buffalo sera displayed neutralis-
ing activity against PPRV (Fig. 2B), all of which had tested negative
previously by cELISA. 59 goat sera were screened for neutralising
antibodies, yielding 36 positive sera, 14 of which were negative
by cELISA (Fig. 2C). In combination, screening of these gazelle, buf-
falo and goat sera suggested that the cELISA had a positive predic-
tive value of 100%; all positives detected by cELISA harbouring
neutralising antibodies. In contrast, the negative predictive value
of the cELISA was 71%; 29% of ELISA negatives possessing neutral-
ising antibodies. As the cELISA detects the competitive inhibition of
anti-PPRV H monoclonal antibody binding, it is possible that the
low negative predictive value reflects differences in the epitope
specificity of the antiviral immune response across host species.
Next, we examined the species-specificity of the PPRV
neutralising antibodies in the buffalo and goat sera, comparing
PPRV titres with those against RPV and CDV. The buffalo sera did
not neutralize RPV; however, 5 sera neutralized CDV, only 2 of
which had anti-PPRV activity, indicative of a cross-reactive
response. The remaining 3 animals recognized CDV but neither
PPRV nor RPV, suggesting a primary exposure to CDV or an
antigenically-related ruminant morbillivirus. In comparison with
the buffalo sera, several goat sera displayed cross-neutralising
activity against RPV (Fig. 3A). In general, this activity increased
with anti-PPRV titre (Spearman r = 0.7366, p < 0.0001). Similarnoculum
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Fig. 2. PPRV neutralising antibodies in sera from Tanzanian ruminants. Sera from (A) gazelle (n = 27), (B) buffalo (n = 42) or (C) goats (n = 59) were screened by competitive
ELISA (cH-ELISA) for anti-PPRV H antibodies and a ‘‘percent inhibition” calculated for each sample. The samples were then re-screened for neutralising antibodies against VSV
(PPRV) pseudotypes. Serial dilutions of each serum sample were prepared in triplicate and screened for neutralising activity against VSV(PPRV) pseudotypes (Nigeria/75/1).
Antibody titres were calculated based on a 90% reduction of infectivity relative to the no serum control. Samples which tested negative for neutralising antibodies are shown
in blue, those which tested positive for PPRV neutralising antibodies are highlighted in red. The 50% cut-off above which a sample is declared positive by the cH-ELISA is
denoted by a grey line. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 3. Comparison of neutralising antibody titres against VSV(PPRV) with those against VSV(RPV), VSV(CDV) or PPRV live virus. Goat sera were screened simultaneously for
neutralising activity against VSV pseudotypes bearing PPRV (Nigeria/75/1) and either (A) RPV (Kabete O) or (B) CDV (Onderstepoort) glycoproteins. (C) In a separate
experiment, sera from cattle vaccinated with live attenuated RPV (blue circles) or PPRV (red circles) vaccines and with known antibody titres against live PPRV Nigeria/75/
1virus, were re-screened for neutralising activity against VSV(PPRV Nigeria/75/1). Antibody titres in the pseudotyped virus assay (A,B,C) were calculated based on a 90%
reduction of infectivity relative to the no serum control (three replicates per dilution). Antibody titres in the live virus based assay (C) were expressed as the reciprocal of the
antibody dilution at which 50% of the wells showed virus growth (six replicates per dilution). (For interpretation of the references to color in this figure legend, the reader is
referred to the web version of this article.)
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goat sera and the corresponding anti-CDV responses (Fig. 3B),
albeit with a weaker correlation (Spearman r = 0.6002,
p < 0.0001). Antibody titres obtained with the pseudotyped virus
neutralisation assay correlated well with the titres obtained by live
virus neutralisation assay (Fig. 3C) albeit with an increased sensi-
tivity. PPRV neutralising antibody titres in 72 serum samples from
cattle vaccinated with live attenuated PPRV or RPV vaccines (as
described in [31] and Fig. 1) were estimated using either VSV(PPRV
Nigeria/75/1) on 293-dogSLAM cells or replication competent PPRV
Nigeria/75/1 virus on Vero dogSLAM cells. Titres correlated well
between both assay systems (Spearman r = 0.89, p < 0.0001). The
pseudotyped virus assay yielded titres approximately 100-fold
higher than the ‘‘live virus”-based assay with 10 of the 72 sera that
were negative by live virus neutralisation assay testing positive by
the pseudotyped virus test.
3.3. Cross-reactivity between PPRV and RPV neutralising antibodies
Previously, we noted cross-neutralisation between the anti-
PPRV and anti-CDV responses in sera from both naturally infected
and vaccinated animals [32]. To characterize the degree ofcross-neutralisation between PPRV and RPV, we compared sera
from animals exposed to either PPRV or RPV for the presence of
cross-neutralising antibodies against the heterologous virus
(Fig. 4). The sera raised against RPV and PPRV clustered into two
distinct groups, irrespective of the two sets of sera being derived
from different host species and having been raised against a range
of viral strains. Hence the RPV sera neutralized RPV more effi-
ciently than PPRV while the PPRV sera neutralized PPRV more effi-
ciently than RPV. Moreover, by comparing the neutralising
antibody titres against PPRV and RPV, it was possible to predict
whether an animal had been exposed to PPRV or RPV.
3.4. Detecting atypical morbillivirus infections
While PPRV is primarily a pathogen of sheep and goats, it can
infect sub-clinically a range of species (reviewed in [33]). Subse-
quent to a PPRV outbreak in the Serengeti ecosystem in 2008,
the presence of PPRV was confirmed in cattle in Northern Tanzania
[34]. Previously, RPV vaccination of cattle would have induced
cross-protective immunity against PPRV; however, following the
global eradication of rinderpest and the cessation of RPV vaccina-
tion, the presence of PPRV in cattle may indicate that the absence
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5740 N. Logan et al. / Vaccine 34 (2016) 5736–5743of cross-protective immunity has facilitated the spread of PPRV
into atypical hosts. Hence, an enhanced immunosurveillance of
both domestic and non-domestic species may establish the poten-
tial reservoir species that should be targeted during future PPRV
eradication campaigns. Accordingly, we screened cattle sera from103
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antibodies against PPRV, CDV and RPV (Fig. 5). Of 125 serum sam-
ples screened, 4 samples were identified with PPRV-specific neu-
tralising activity (samples 83, 155, 211 and 236). Surprisingly, we
also detected 5 samples with RPV-specific activity (56, 70, 118,
170 and 192) and a further two samples (125 and 197) with high
activity against RPV and cross-neutralising activity against PPRV.
Further, 2 samples neutralized CDV specifically (samples 195 and
204). Hence, we were able to confirm the exposure of cattle to
PPRV (4/125, 3.2%), an RPV-like virus (7/125, 5.6%) and CDV
(2/125, 1.6%). Given the cessation of rinderpest vaccination in Tan-
zania in 1998 and the confirmation of rinderpest eradication in
Tanzania in 2003, the detection of RPV-specific antibodies in
2009 is of significant interest. The samples that displayed RPV-
specific neutralisation were screened against an extended panel
of morbillivirus pseudotypes including MeV and PDV, and com-
pared with sera raised against MeV, CDV, PPRV or RPV (Fig. 6).
Human serum from an MMR-vaccinate neutralized MeV efficiently
and displayed good cross-neutralisation of RPV and PPRV, with
weak activity against CDV (Fig. 6a). Conversely, serum from an
RPV-vaccinated animal neutralized RPV most efficiently but dis-
played cross-neutralisation of CDV, PPRV and MeV (Fig. 6a). The
sera from a CDV-vaccinate and a PPRV-vaccinate neutralized their
respective homologous viruses most efficiently with weaker cross-
neutralisation of other morbilliviruses at high serum concentra-
tions (Fig. 6a). In contrast, the Tanzanian cattle sera (170, 192, 56
and 188) neutralized RPV primarily with only weak cross-
neutralisation of MeV, PPRV or CDV. As the neutralising activity
in these samples was modest in comparison with the sera from
cattle exposed to RPV experimentally (Figs. 1 and 4), the specific
neutralisation of RPV by these samples may reflect lower antibody
titres in the sera per se. However, the specificity of the sera for RPV
may also indicate that the virus to which they were exposed is aR
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Fig. 6. Cross-neutralising activity in sera from Tanzanian cattle. (A) VSV pseudotypes were generated bearing glycoproteins from CDV, PPRV, RPV, MeV or PDV and their
sensitivity to neutralisation by sera raised against MeV, CDV, PPRV and RPV compared. (B) Sera from four Tanzanian cattle with anti-RPV activity were screened for cross-
neutralisation of CDV, PPRV, MeV and PDV. RPV neutralisation was the dominant activity in the serum samples. Each neutralisation assay was repeated on three independent
occasions, typical result shown. Each point represents the mean ± SEM (n = 3).
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gent from MeV, CDV and PPRV. Given that all the sera we have
tested to date displayed a higher titre of neutralising antibody
against their homologous morbillivirus, the data suggest that these
Tanzanian cattle were exposed to an RPV-like bovine morbillivirus.4. Discussion
The OIE has identified PPR as a global priority for eradication.
PPRV continues to spread globally [35,36], with over 1 billion sheep
and goats at risk from infection, approximately 80% of the world’s
small ruminants [37]. RPV eradication led to the cessation of vacci-
nation and, as a result, there are fears that morbilliviruses such as
PPRV or CDV could spill over into the global population of 1.5 billion
immunologically-naïve cattle [38]. Indeed, PPRV seropositive cattle
have now been identified in countries across Africa and Asia [39–
42]. Understanding the patterns of morbillivirus infections in
domestic livestock andwildlife populationswill be critical to ensur-
ing the success of future global eradication programs.
To validate the sensitivity of the pseudotype-based assay for
PPRV neutralising antibodies, we screened sera from three groups
of cattle, one infected with a wild type strain of PPRV (IC89) and
two vaccinated with live attenuated PPRV vaccines (N75 and
S96). Animals infected with IC89 developed significantly higher
antibody titres, antibodies that cross-neutralized PPRV strains
from each of the four lineages. These data suggest that an animal
exposed to a virus such as IC89, and which had recovered and gen-
erated a strong humoral response, would be cross-protected from
infection with viruses from all four lineages. In contrast, the neu-
tralising responses of the sera from animals vaccinated with N75
or S96 generated significantly lower titres of neutralising antibod-
ies in comparison with the IC89-infected animals. Lineage 2 N75
and lineage 4 S96-containing vaccines are licenced in severalPPRV-endemic countries. Neutralising antibody titres induced by
the two vaccines were highest against the vaccine strain N75,
and lowest against lineage 3 Kenya 2011. Such observations may
assist the design of future eradication strategies and retrospective
analyses of sera from vaccine trials might provide an insight into
whether the level of neutralising antibody induced by vaccination
correlates with immunity to infection with viruses from distinct
lineages. In this study, we were restricted to the examination of
sera from cattle infected experimentally with PPRV. Future studies
should examine sequential sera from goats and sheep, the primary
targets for PPRV vaccination campaigns, as it is likely that the repli-
cation of live attenuated viruses will vary between target species
and hence the strength and breadth of immunity induced will vary
accordingly.
The high sensitivity of the pseudotype-based assay facilitated
the detection of a higher proportion of sero-positives than a widely
used ELISA. While it should be noted that the ELISA was optimised
for specificity, allowing PPRV exposure in a herd to be confirmed, it
was evident that the assay sensitivity was low, underestimating
the number of positive animals significantly. Indeed, three animals
with high titre neutralising antibodies tested negative by ELISA.
Presumably the humoral response in those animals targeted epi-
topes on PPRV H distinct to that recognised by the monoclonal
antibody within the kit or targeted the PPRV F protein.
We detected PPRV neutralising responses in sera from both buf-
falo and goats. The presence of neutralising antibodies in 38% of
buffalo sera that had tested negative previously by ELISA suggests
that PPRV exposure was under-reported in previous studies [34].
The presence of PPRV in Serengeti buffalo is consistent with find-
ings of PPRV antibody-positive wildlife species in the vicinity
[43]. The detection of CDV-specific antibodies in 5 of the buffalo
indicates that morbillivirus exposure in wildlife is not restricted
to PPRV and is consistent with findings of CDV seropositivity in
lions within the same ecosystem [44]. The co-circulation of PPRV
5742 N. Logan et al. / Vaccine 34 (2016) 5736–5743and CDV in the same livestock and wildlife species may interfere
with the accurate diagnosis of PPRV infection using existing sero-
logical techniques. The pseudotype-based neutralisation test may
offer additional, rapid discrimination of findings.
By comparing batches of experimental sera from animals
exposed to either RPV or PPRV, we demonstrated that the neutral-
ising responses were highest against the homologous virus, consis-
tent with the original serology-based evidence for the distinction
of RPV and PPRV [45–48]. Accordingly, we are able to examine
banks of sera for historical exposures to morbilliviruses and to pre-
dict the nature of the infecting agent. Using this approach, we
demonstrated that cattle in three villages in Tanzania had been
exposed to not only PPRV, but also CDV, consistent with the earlier
findings with buffalo sera. Intriguingly, seven animals had neutral-
ising antibodies targeted primarily against RPV, two of which also
cross-neutralized PPRV efficiently. Given that (a) rinderpest vacci-
nation ceased in this region in 1997, (b) three of the seven animals
were <5 years of age and (c) positive animals were detected in cat-
tle from three separate villages, the presence of anti-RPV antibod-
ies in 2009 suggests a recent exposure to an RPV-related bovine
morbillivirus. There is a compelling precedent for the existence
of an RPV-related bovine morbillivirus in cattle populations. In
1975, a ‘‘bovine paramyxovirus” was isolated from cattle display-
ing symptoms of sporadic encephalomyelitis in Germany and
Switzerland [49]. Serological tests on cells infected with the agent
confirmed reactivity with sera raised against RPV, or convalescent
sera from measles patients with sub-acute sclerosing panen-
cephalitis (SSPE) [49]. In 1976, a morbillivirus was identified in cat-
tle affected with malignant catarrhal fever in Colorado [50].
Immunofluorescence studies of tissues from an infected animal
reacted strongly with serum from an animal infected with the
Kabete ‘‘O” strain of RPV but only weakly with sera raised against
MeV or CDV [50]. In 1998, an investigation of sporadic outbreaks of
non-suppurative meningoencephalomyelitis in Swiss cattle noted
that four cases displayed immunoreactivity with monoclonal anti-
bodies raised against either RPV or CDV nucleocapsids [51]. The
existence of an RPV-related bovine morbillivirus may also explain
why an animal in a previous rinderpest vaccine trial displayed neu-
tralising antibodies against RPV prior to vaccination [52]. Given
that recent studies have revealed the astonishing diversity of
paramyxoviruses circulating in bats and rodents [53], we should
expect that many more paramyxoviruses await discovery in other
species. Indeed, a morbillivirus of domestic cats has recently been
described, a virus that appears to be relatively widespread globally
[54–56]. The data presented here may suggest an additional bovine
morbillivirus is circulating, with possible implications for PPRV
diagnostics, surveillance and vaccination.
If vaccination to eradicate PPR is to succeed, future studies
should address which species act as reservoirs of infection and
whether they may shed infectious virus. If species such as cattle
shed infectious PPRV, this must be taken into consideration in a
post-PPRV eradication environment. Continued immunosurveil-
lance will ascertain whether PPRV is spreading more widely;
broadening its host species in a post-RPV world. Finally, we should
consider whether RPV eradication has created a vacated niche [57]
for PPRV other morbilliviruses such as CDV, or a novel RPV-related
bovine morbillivirus.
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